Pharma BD Deal Intelligence
Novartis paid ~$880M for full control of Tekturna/Rasilez, then took a ~$900M impairment on it three years later and sold the wreckage off in 2016 for a fraction of the price.
Full analysis, sources & comparables →The pre-deal royalty dispute — Speedel disputing CHF cost-of-goods payments and audit rights — gave Novartis a clear strategic reason to fully integrate the…
The ALTITUDE trial halt in December 2011 — increased stroke, kidney complications, hyperkalemia, and hypotension in diabetics on aliskiren plus ACE/ARB —…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
CHF 907M total; renin inhibitor (aliskiren/Tekturna); CHF 130/share
Novartis paid ~$880M for full control of Tekturna/Rasilez, then took a ~$900M impairment on it three years later and sold the wreckage off in 2016 for a fraction of the price.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Speedel Holding AG (this deal) | 2008 | $880M | 16 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2008 deals · Novartis AG deals